ArticleMuscles (Basel, Switzerland)2025
Association of Skeletal Muscle Radiodensity and Skeletal Muscle Index with Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer.
Article in Muscles (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia and reduced skeletal muscle radiodensity have been proposed as potential biomarkers influencing the outcomes of immunotherapy in cancer patients. This retrospective study aimed to evaluate the prognostic significance of skeletal muscle index (SMI) and skeletal muscle radiodensity (SMD), assessed by means of computed tomography imaging at the L3 level, in 76 male patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. Patients were categorized into high and low SMI/SMD groups based on body mass index-adjusted cut-off values. Clinical outcomes included treatment response, overall survival, and immune-related adverse events. While no statistically significant differences in overall survival were observed between groups stratified by SMI or SMD, patients with higher SMD demonstrated a significantly greater disease control rate (56.22 ± 8.04 vs. 48.36 ± 10.34 HU;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.